Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

BACKGROUND: Anlotinib showed encouraging anti-tumor activity in metastatic colorectal cancer (mCRC). This study was designed to assess the efficacy and safety of anlotinib plus XELOX as first-line therapy in mCRC patients. MATERIALS AND METHODS: Eligible patients aged ≥18 with mCRC were enrolled in...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Bo, Hu, Hai, Zhang, Li, Ye, Su-Juan, Jin, Yong-Dong, Shang, Chang-Ling, Zhang, Jun, Sun, Hao, Zhang, Ke, Yi, Bo, Han, Yun-Wei, Yan, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505961/
https://www.ncbi.nlm.nih.gov/pubmed/37727206
http://dx.doi.org/10.3389/fonc.2023.1238553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505961/
https://www.ncbi.nlm.nih.gov/pubmed/37727206
http://dx.doi.org/10.3389/fonc.2023.1238553

Ejemplares similares